Abbott Laboratories (ABT) operating KPIs
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — Worldwide Revenue ($M) ($M)
Beginning in Q1 2026, Abbott combined Rapid Diagnostics, Molecular Diagnostics, and Point of Care into Rapid and Molecular Diagnostics.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — Worldwide Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 899 | – | SEC Filing (0001628280-26-066601) ↗ |
| Q2 2026 | Jun 30, 2026 | 755 | -7.4% | SEC Filing (0001628280-26-048377) ↗ |
| Q1 2026 | Mar 31, 2026 | 812 | -7.4% | SEC Filing (0001628280-26-025365) ↗ |
| Q2 2025 | Jun 30, 2025 | 815 | – | SEC Filing (0001628280-26-050134) ↗ |
| Q1 2025 | Mar 31, 2025 | 877 | – | SEC Filing (0001628280-26-028357) ↗ |
Breakdown
What makes up rapid and molecular diagnostics division (combined subsegment from q1 2026) — worldwide revenue ($m)
- Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — Organic / Comparable Sales Growth (%)0.9% · Q3 2026
- Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — Reported Sales Growth (%)1.1% · Q3 2026
- Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — U.S. Revenue ($M)526 · Q3 2026
- Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — International Revenue ($M)373 · Q3 2026
Cite this data
StockData. (2026). Abbott Laboratories Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — Worldwide Revenue ($M) ($M), quarterly Q1 2025–Q3 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-rm-rev-ww
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.